Johnson & Johnson CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
FDA Mandates New Safety Warnings for ADHD Stimulants in Children Under Six
The FDA is revising labeling for all extended-release ADHD stimulants to include warnings about weight loss and adverse reactions in children under six years old.
AbbVie Acquires In Vivo CAR-T Developer Capstan Therapeutics for Up to $2.1 Billion
AbbVie has agreed to acquire cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion in cash, gaining access to innovative in vivo CAR-T technology.
Federal Court Rejects Johnson & Johnson's 340B Drug Pricing Rebate Model
A federal court ruled against Johnson & Johnson's proposal to shift from upfront drug discounts to a rebate model in the 340B Drug Pricing Program, which requires pharmaceutical manufacturers to sell outpatient drugs at reduced prices to healthcare providers serving low-income and rural populations.
FDA Removes Regulatory Barriers for Bristol Myers Squibb's CAR T-Cell Therapies, Expanding Patient Access
The FDA eliminated Risk Evaluation and Mitigation Strategy (REMS) programs and reduced post-treatment monitoring from four weeks to two weeks for Bristol Myers Squibb's CAR T-cell therapies Breyanzi and Abecma.
Johnson & Johnson Expands Tecnis Odyssey IOL to Europe, Middle East, and Canada Following US Success
Johnson & Johnson has launched the Tecnis Odyssey IOL in Europe, the Middle East, and Canada, expanding access to its presbyopia-correcting intraocular lens technology.
UK Flair Trial Demonstrates Superior Outcomes with Chemotherapy-Free Combination Therapy for Chronic Lymphocytic Leukaemia
The UK-wide Flair trial involving 786 patients showed that 94% of chronic lymphocytic leukaemia patients receiving ibrutinib plus venetoclax were alive with no disease progression after five years, compared to 79% on ibrutinib alone and 58% on standard chemotherapy.
COVID-19 Vaccination Reduces Severe Kidney Damage Risk in Hospitalized Patients, UCLA Study Finds
UCLA Health researchers analyzed 3,500 hospitalized COVID-19 patients and found unvaccinated individuals were 16% more likely to require continuous renal replacement therapy during hospitalization.
Johnson & Johnson's Dual-Targeting CAR-T Therapy Achieves 80% Complete Response Rate in Lymphoma Trial
Johnson & Johnson's investigational dual-targeting CAR-T therapy JNJ-4496 demonstrated 75-80% complete response rates in patients with relapsed or refractory large B-cell lymphoma at the recommended Phase 2 dose.
Johnson & Johnson's Bleximenib Shows Promising Results in Phase 1b AML Trial with 82% Response Rate
Johnson & Johnson's investigational menin inhibitor bleximenib demonstrated an 82% overall response rate in relapsed/refractory AML patients when combined with venetoclax and azacitidine in Phase 1b trials.
Comprehensive Analysis Reveals 943 Autoimmune Collaboration and Licensing Deals Across 30 Diseases from 2016-2025
A new comprehensive report analyzes 943 autoimmune collaboration and licensing deals from 2016-2025, covering over 30 diseases including multiple sclerosis, rheumatoid arthritis, lupus, and Crohn's disease.